OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control....

New data provide proof-of-concept for VBL's proprietary MOSPD2 bi-specific antibodies, observing survival benefit and no evidence of toxicity in a model of metastatic human cervical cancer TEL AVIV, Israel , May 18, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) announced today that new...

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , May 14, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2020 , and provided a corporate update. “We reached an important milestone in our...

Raised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings TEL AVIV, Israel , May 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced offering of 5,142,857 ordinary shares of the Company, at a purchase price...

TEL AVIV, Israel , May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced...

TEL AVIV, Israel , May 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in...

Study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction Data demonstrate the potential of VBL's proprietary MOSPD2 mAbs for chronic inflammatory indications, via a novel and distinct mechanism targeting monocyte migration TEL AVIV, Israel , May 06,...

TEL AVIV, Israel , May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast...

Data were published in a peer-review manuscript in Clinical & Experimental Immunology TEL AVIV, Israel , May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) is pleased to announce the publication of a new manuscript demonstrating the potential of MOSPD2 antibodies for Multiple...

TEL AVIV, Israel , April 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS) (approximately $0.9 million ) by the Israel Innovation Authority (IIA). The IIA has approved a budget...